Cardiff Oncology Inc CRDF

NAS: CRDF | ISIN: US14147L1089   14/05/2024
3,580 USD (+2,87%)
(+2,87%)   14/05/2024

17 januari 2024 · Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research · Persbericht

2 november 2023 · Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update · Persbericht

26 oktober 2023 · Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update · Persbericht

26 september 2023 · Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy · Persbericht

5 september 2023 · Cardiff Oncology to Present at Upcoming Investor Conferences in September · Persbericht

9 augustus 2023 · Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update · Persbericht

7 augustus 2023 · Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship · Persbericht

24 juli 2023 · Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 juni 2023 · Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 juni 2023 · Cardiff Oncology to Present at the Jefferies Healthcare Conference · Persbericht

4 mei 2023 · Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update · Persbericht

28 maart 2023 · Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer · Persbericht

6 maart 2023 · Cardiff Oncology Formally Introduces Scientific Advisory Board · Persbericht

2 maart 2023 · Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update · Persbericht

27 februari 2023 · Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference · Persbericht

2 februari 2023 · Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer · Persbericht

10 januari 2023 · Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference · Persbericht

21 november 2022 · Cardiff Oncology to Present at Upcoming Investor Conferences · Persbericht

8 november 2022 · Cardiff Oncology to Present at the Jefferies London Healthcare Conference · Persbericht

3 november 2022 · Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates · Persbericht

Mijn selecties